| October 2, 2014 | ISSUE NUMBER 371 VOL 4 |
|
Compliance
“Sunshine” Goes Live – Despite Data Concerns
The federal Open Payments program went live on September 30 — even though 40% of the data is “de-identified” — ignoring calls from medical societies and drug manufacturers urging a delay to the launch of the program for fear that the public would be confused by the incomplete information. Jill Wechsler reports ...Read more
Pharma Marketing
Email Marketing Grows Up
Email marketing is still very much with us, despite much talk of its demise. But, writes Peter Houston, it has moved on from its “spammy” adolescence. This is thanks to its role as the corner-stone of multichannel marketing, a unique identifier at the center of a 360-degree view of the customer ...Read more
Covance MarketPlace. Connect Right from the Start.
Find the right partner with the desire and resources to help you realize your molecule’s potential. Through our private, secure and exclusive online portal, you can share information about your molecule to potential investors or partners. It's one more innovative way to transform the profile and success of your program, delivered by the only global drug development partner with expertise spanning preclinical, clinical and commercial phases.  Learn more
Europe
Trouble Brewing on European Pricing Horizon
"Better volcano forecasting", the European Union announced with pride in mid-September. The breakthrough was a new EU-funded monitoring scheme for Iceland's volatile geology. What the EU has paid less attention to is the volcano that is soon likely to blow apart its assumptions on the pricing and reimbursement of medicines, writes our Brussels correspondent Reflector
...Read more
Emerging Markets
Investing in African Healthcare: Study, Share, Act — and Grow
Is sub-Saharan Africa a jewel box of untapped assets for a growth-obsessed big Pharma? Some of the majors apparently think so. To identify some benchmarks for best practices in building a viable drugs business in Africa, we spoke to Steven Adjei, native Ghanaian and founding partner of a start-up business “incubator” firm focused on opportunities in the sub-Saharan region
...Read more
|
|
|
|
 //Ritter Pharmaceuticals (Los Angeles, CA) named Michael D. Step as Chief Executive Officer. Founder Andrew Ritter will hold the title of President while continuing as a Director.//Inovio Pharmaceuticals (Plymouth Meeting, PA) announced the appointment of Jennifer Laux as Vice President, Commercial.// IRetrophin (New York, NY) announced a leadership reorganization under which the Board of Directors has appointed Stephen Aselage as interim Chief Executive Officer (CEO), effective immediately, to replace Martin Shkreli, Founder and CEO.//Intellipharmaceutics International (Toronto, Canada) announced the resignation of Shameze Rampertab, Vice President, Finance and Chief Financial Officer, who is leaving October 10 to take up a role in the medical devices industry. The company has commenced a search to fill Mr. Rampertab’s role.// |
|
|
|
|
|
 |
|
 |
|
| |
 |
|
 |
 Which of these countries do you believe will drive most of pharma's growth over the next 12 months?
|
|
|
|
